Final Glance: Medical Devices companies
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
J&J's Velcade in Focus at the European Hematology Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:20PM CDT
Johnson & Johnson (JNJ) presented encouraging data from a phase III study on its oncology drug, Velcade, at the annual meeting of the European Hematology Association.
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
PR Newswire - Tue Jun 17, 4:00PM CDT
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 15th, to review second-quarter results. Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer; Dominic Caruso, Vice President, Finance and Chief Financial Officer; Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals; Joaquin Duato, Worldwide Chairman, Pharmaceuticals; and Louise Mehrotra, Vice President, Investor Relations, will host the call.
Drugs Drive Growth For Johnson & Johnson
at Investor's Business Daily - Tue Jun 17, 3:58PM CDT
At 128 years old, Johnson & Johnson (JNJ) is still delivering growth and income for its shareholders. It's not Band-Aid bandages and baby oil that's driving growth for the New Brunswick, N.J.-based health-care giant. Out of its three operating units,...
Beck Expands Team With Experienced Director of Operations
PRWeb - Tue Jun 17, 3:04PM CDT
Beck, a print reproduction process authority specialized in enhancing a brand's image on the shelf or any media output, has expanded its executive leadership team with the addition of Jimmy Watkins as Director of Operations. Mr. Watkins brings more than 20 years of design and packaging commercialization expertise, and will be responsible for identifying and implementing process improvements to optimize a brand's color consistency and printed image.
ExxonMobil, Johnson & Johnson Tumble as Dow Gains
Dan Carroll, The Motley Fool - Motley Fool - Tue Jun 17, 1:39PM CDT
The market has struggled to stay on course today, and the Dow Jones Industrial Average beat back earlier losses to rise 35 points into the green as of 2:35 p.m. EDT. Twelve of the blue-chip index's 30 member stocks were in the red. ExxonMobil ...
3-D Printing Company Materialise Prices IPO and Is Expected to Begin Trading on June 24
Beth McKenna, The Motley Fool - Motley Fool - Tue Jun 17, 1:03PM CDT
The 3-D printing stocks have taken a bruising in 2014, but that's not stopping Belgium-based Materialise from throwing its hat into the publicly traded ring. IPO terms were released last week, so we can now explore these questions: Does this...
Midday Glance: Medical Devices companies
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Johnson & Johnson (JNJ) Crosses Pivot Point Support at $101.90
Comtex SmarTrend(R) - Tue Jun 17, 11:42AM CDT
Johnson & Johnson (NYSE:JNJ) has opened bearishly below the pivot of $102.39 today and has reached the first level of support at $101.90. Should the shares continue to fall, the support pivots of $101.34 and $100.29 will be of interest.
Early Glance: Medical Devices companies
AP - Tue Jun 17, 9:39AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jun 17, 9:39AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global
RF Micro Devices, Select Income Reality, TriQuint Semi, Medtronic,Covidien, Johnson & Johnson, iShares U.S. Medical Devices ETF, Pfizer and AstraZeneca highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jun 17, 8:30AM CDT
Zacks Equity Research highlights RF Micro Devices (Nasdaq:RFMD-Free Report) as the Bull of the Day and Select Income Reality (NYSE:SIR-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onTriQuint Semi (Nasdaq:TQNT-Free Report), Medtronic (NYSE:MDT-Free Report), Covidien (NYSE:COV-Free Report), Johnson & Johnson (NYSE:JNJ-Free Report), iShares U.S. Medical Devices ETF (AMEX:IHI-Free Report), Pfizer (NYSE
Better Stock Today Challenge: Johnson & Johnson vs. DistributionNow
David Williamson and Joel South, The Motley Fool - Motley Fool - Mon Jun 16, 3:20PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Johnson & Johnson takes on ...
Will Medtronic's Deal for Covidien Push Stryker to Smith & Nephew?
at The Street - Mon Jun 16, 12:32PM CDT
For Stryker, this deal would be accretive within the first full year of completion, generating immediately value for shareholders of both companies.
Medtronic's Acquisition Isn't Just About Lowering Its Tax Bill
at The Street - Mon Jun 16, 12:27PM CDT
There's more to its buying competitor Covidien for $42.9 billion.
Medtronic Buying Covidien, Becoming Device Colossus
at Investor's Business Daily - Mon Jun 16, 9:33AM CDT
Shares of medical device maker Covidien (COV) jumped 28% to above 92 on the stock market today after Medtronic (MDT) announced late Sunday that it is buying the company for $43 billion. Medtronic's cash-and-stock payment amounts to $93.22 a share,...
Johnson & Johnson Scores a Solid Hit With Imbruvica
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Jun 16, 8:30AM CDT
The biggest cancer conference of the year is over, and star talent Imbruvica one out of the ballpark for its Big Pharma part-owner, Johnson & Johnson . Shares of Johnson & Johnson outperformed the S&P 500 since the beginning of the...